299 related articles for article (PubMed ID: 32682086)
1. Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis.
Chatterjee A; Basu A; Das K; Singh P; Mondal D; Bhattacharya B; Roychoudhury S; Majumder PP; Chowdhury A; Basu P
Ann Hepatol; 2020; 19(5):472-481. PubMed ID: 32682086
[TBL] [Abstract][Full Text] [Related]
2. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
3. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.
Krishnan A; Abdullah TS; Mounajjed T; Hartono S; McConico A; White T; LeBrasseur N; Lanza I; Nair S; Gores G; Charlton M
Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G666-G680. PubMed ID: 28232454
[TBL] [Abstract][Full Text] [Related]
4. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance, but not insulin response, during oral glucose tolerance test (OGTT) is associated to worse histological outcome in obese NAFLD.
Coccia F; Testa M; Guarisco G; Di Cristofano C; Silecchia G; Leonetti F; Gastaldelli A; Capoccia D
Nutr Metab Cardiovasc Dis; 2020 Jan; 30(1):106-113. PubMed ID: 31677889
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
7. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.
Polyzos SA; Kountouras J; Papatheodorou A; Katsiki E; Patsiaoura K; Zafeiriadou E; Papadopoulou E; Zavos C; Terpos E
Ann Hepatol; 2013; 12(5):749-57. PubMed ID: 24067262
[TBL] [Abstract][Full Text] [Related]
8. Identification of transcriptomic signatures and crucial pathways involved in non-alcoholic steatohepatitis.
He W; Huang C; Zhang X; Wang D; Chen Y; Zhao Y; Li X
Endocrine; 2021 Jul; 73(1):52-64. PubMed ID: 33837926
[TBL] [Abstract][Full Text] [Related]
9. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
[TBL] [Abstract][Full Text] [Related]
10. Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression.
Azzu V; Vacca M; Kamzolas I; Hall Z; Leslie J; Carobbio S; Virtue S; Davies SE; Lukasik A; Dale M; Bohlooly-Y M; Acharjee A; Lindén D; Bidault G; Petsalaki E; Griffin JL; Oakley F; Allison MED; Vidal-Puig A
Mol Metab; 2021 Jun; 48():101210. PubMed ID: 33722690
[TBL] [Abstract][Full Text] [Related]
11. The role of bariatric surgery on beta-cell function and insulin resistance in patients with nonalcoholic fatty liver disease and steatohepatitis.
Poljo A; Kopf S; Sulaj A; Roessler S; Albrecht T; Goeppert B; Bojko S; Müller-Stich BP; Billeter AT
Surg Obes Relat Dis; 2023 Dec; 19(12):1421-1434. PubMed ID: 37666725
[TBL] [Abstract][Full Text] [Related]
12. Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
Enooku K; Tsutsumi T; Kondo M; Fujiwara N; Sasako T; Shibahara J; Kado A; Okushin K; Fujinaga H; Nakagomi R; Minami T; Sato M; Uchino K; Nakagawa H; Kondo Y; Asaoka Y; Tateishi R; Ueki K; Ikeda H; Yoshida H; Moriya K; Yotsuyanagi H; Kadowaki T; Koike K
J Gastroenterol; 2020 Feb; 55(2):227-243. PubMed ID: 31602526
[TBL] [Abstract][Full Text] [Related]
13. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.
Kozumi K; Kodama T; Murai H; Sakane S; Govaere O; Cockell S; Motooka D; Kakita N; Yamada Y; Kondo Y; Tahata Y; Yamada R; Hikita H; Sakamori R; Kamada Y; Daly AK; Anstee QM; Tatsumi T; Morii E; Takehara T
Hepatology; 2021 Nov; 74(5):2452-2466. PubMed ID: 34105780
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology.
Jung KY; Cho SY; Kim HJ; Kim SB; Song IH
J Clin Gastroenterol; 2014; 48(10):883-8. PubMed ID: 24440936
[TBL] [Abstract][Full Text] [Related]
15. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.
Pais R; Charlotte F; Fedchuk L; Bedossa P; Lebray P; Poynard T; Ratziu V;
J Hepatol; 2013 Sep; 59(3):550-6. PubMed ID: 23665288
[TBL] [Abstract][Full Text] [Related]
17. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
[TBL] [Abstract][Full Text] [Related]
18. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.
Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS
Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162
[TBL] [Abstract][Full Text] [Related]
19. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
20. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease.
Fujii H; Kawada N; Japan Study Group Of Nafld Jsg-Nafld
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32485838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
